enVVeno Medical's VenoValve proves effective in study
The FDA has requested at least one year of data from the trial before enVVeno can apply for premarket approval.
Source: yahoo.com
Page 2 - Robert Berman News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Robert Berman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Robert Berman Today - Breaking & Trending Today
Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medica
Overall 8.46 Average Revised Venous Clinical Severity Score (rVCSS) Improvement Per Patient for Patients Showing Clinical Meaningful Benefit (rVCSS Improvement ≥ 3 Points) including:9.29 Points for Patients at the Two-Year Milestone8.08 Points for Patients at the One-Year Milestone8.71 Points for Patients at the Six...
Source: pharmiweb.com
While institutions own 29% of Rekor Systems, Inc. (NASDAQ:REKR), individual investors are its largest shareholders with 46% ownership
Key Insights The considerable ownership by individual investors in Rekor Systems indicates that they collectively have...
Source: yahoo.com
enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer ...
EnVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer ...
Source: pr-inside.com
Rekor Systems, Inc. (NASDAQ:REKR) Q4 2023 Earnings Call Transcript
Rekor Systems, Inc. misses on earnings expectations. Reported EPS is $-0.16 EPS, expectations were $-0.11. Rekor Systems, Inc.
Source: insidermonkey.com